Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- 15 November 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in BioDrugs
- Vol. 30 (6), 571-584
- https://doi.org/10.1007/s40259-016-0204-3
Abstract
Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have shown durable treatment responses in multiple tumor types by enhancing antitumor immunity. However, removal of self-tolerance can induce autoimmunity and produce a unique immune-driven toxicity profile, termed immune-related adverse events (irAEs). As ICIs gain approval for a growing number of indications, it is imperative clinicians increase their knowledge of and ability to manage irAEs. This review examines the etiology, presentation, kinetics, and treatment of irAEs and aims to provide practical guidance for clinicians.Keywords
Funding Information
- Ontario Institute for Cancer Research (OICR Research Fellow)
This publication has 100 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Induced sensitization of tumor stroma leads to eradication of established cancer by T cellsThe Journal of Experimental Medicine, 2007
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002